true

BD India’s concerted commitment towards creating awareness on Cervical Cancer

India Cervical Cancer Awareness Banner
Publish date: Mar 04, 2024

‘Shape the Future of Women’s Health’ engages 10,000+ Pathologists and Gynecologists in the dialogue on Cervical Cancer awareness

Delhi, March 04, 2024: To create awareness and enable knowledge-sharing around cervical cancer screening, especially the benefits of early screening with liquid-based cytology and human papillomavirus (HPV) DNA testing, BD (Becton, Dickinson, and Company) conducted roadshows across several Indian cities recently. The roadshows were organized in Madurai, Trivandrum, Raipur, Bathinda, Indore, and Rishikesh. These initiatives successfully engaged over 10,000+ pathologists, obstetricians, and gynecologists across the country in a dialogue around how early screening and diagnosis of cervical cancer can lead to saving of patient lives thereby reduced mortality. It also brought the spotlight on the benefits of liquid-based cytology over conventional PAP smear and the importance of primary HPV screening for early diagnosis of cervical cancer. 

 

Commenting on the initiative, Atul Grover, Managing Director, BD India/South Asia said, “When detected early, cervical cancer is one of the most successfully treatable forms of cancer and with timely intervention enables saving patient lives.  BD, through initiatives like Shape the Future of Cervical Cancer, is intent on providing awareness-building platforms on benefits of early and improved screening for HPV infections. We are committed to advancing the world of health in partnership and with the support the Obstetric and Gynecological societies, across the country.”

It is noteworthy that cervical cancer ranks as the second most common cancer, however, is one of the most preventable and treatable types of cancer if detected early. When cervical cancer is diagnosed at an early stage, the 5-year relative survival rate is 91% as averse to when cervical cancer is diagnosed after it has spread to nearby tissues, organs, or regional lymph nodes, the 5-year relative survival rate is 60%.

BD also hosted a Fireside Chat in collaboration with the Indian Association of Practicing Pathologists to discuss the utility of Liquid-Based Cytology, along with an awareness campaign on Cervical cancer on social media. Partnerships with regional Obstetric and Gynecological societies as well as pathology societies facilitated meaningful discussions and knowledge exchange. Each event included case-based discussions and live morphology slide interpretation sessions whereby Cytopathologists gained valuable insights into LBC morphology interpretation that in turn help in enhancing diagnostic skills.

BD India offers comprehensive cervical cancer screening solutions viz. BD SurePath(TM) Direct-to-Slide liquid based cytology test, an innovative solution for increasing access of high performance tests, as well as the BD Onclarity(TM) Assay for HPV testing which is the only FDA approved test for at home self-sampling. These products are geared for increasing access to screening tests for women to take charge of their health from the comfort of their homes. This is in line with the WHO endorsement of screening for high-risk HPV subtypes as the most cost-effective strategy and supports self-sampling for its convenience.  

BD India remains committed to fostering awareness and driving progress in the fight against cervical cancer. For more information, please visit BD.com

About BD-India

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to health care. 

  • Follow us
    • Linked In
    • Facebook
    • X
    • Youtube
Quick Links
BD_tag_en_1-Color_Reverse_RGB_TransparentBurst

© 2024 BD. All rights reserved. BD and the BD Logo are trademarks of Becton, Dickinson and Company. All other trademarks are the property of their respective owners.

Disclaimer

Please note, not all products, services or features of products and services may be available in your local area. Please check with your local BD representative.

The information provided herein is not meant to be used, nor should it be used, to diagnose or treat any medical condition. All content, including text, graphics, images and information etc., contained in or available through this literature is for general information purposes only. For diagnosis or treatment of any medical condition, please consult your physician/doctor. Becton Dickinson India Private Limited and or its affiliates, its employees are not liable for any damages/claims to any person in any manner whatsoever.

Becton Dickinson India Private Limited (“BD”) does not run any investment schemes or solicit monies from general public. We have neither authorized any individual or legal entity to either collect money or arrive at any monetary arrangement for or on behalf of BD. BD is not in any way connected to the actions of any such persons. Any person getting lured by such individual and or legal entity in participating in such unscrupulous schemes will be doing so at their own costs and consequences. BD nor any of its affiliates shall not be liable for any claim, loss, or damage, expenses etc. of any nature whatsoever suffered or may be suffered by general public getting participating in such schemes.

true